[Diffuse alveolar hemorrhage in systemic lupus erythematosus]. 2000

L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
I. Belgyógyászati Klinika, Szent-Györgyi Albert Orvostudományi Egyetem, Szeged.

Of the 120 systemic lupus erythematosus (SLE) patients treated by the authors, two have developed diffuse alveolar haemorrhage. The authors' objective is to present this rare, but severe manifestation. Patients 1 and 2 were 66- and 22-year old women, respectively. Both had SLE with multi-organ involvements including diffuse proliferative lupus nephritis. Before the diagnosis of the disease, both patients had experienced pneumonitis that resolved on corticosteroid treatment. Soon after the diagnosis, respiratory failure, haemoptoea and acute anaemia developed, accompanied by a rapid deterioration in the general condition. Chest radiographs revealed bilateral, diffuse, alveolar infiltrates. The pulmonary haemorrhage temporarily ceased in response to corticosteroid treatment, but both patients later died in consequence of active SLE and mixed bacterial and fungal sepsis. Post mortem examination demonstrated fibrosing alveolitis and alveolar bleeding in Patient 1, and an immune complex deposition-induced alveolocapillary inflammation with alveolar haemorrhage in Patient 2. Diffuse alveolar haemorrhage is a life-threatening manifestation of SLE. Its onset may be preceded by episodes of pneumonitis resolving on corticosteroid treatment. An active diagnostic workup, intensive observation and aggressive immunosuppressive treatment are the cornerstones of the management. The early detection and the active treatment of secondary infections are obligatory. The authors consider the most difficult challenge to be the optimum coordination of the above treatment modalities.

UI MeSH Term Description Entries
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D011650 Pulmonary Alveoli Small polyhedral outpouchings along the walls of the alveolar sacs, alveolar ducts and terminal bronchioles through the walls of which gas exchange between alveolar air and pulmonary capillary blood takes place. Alveoli, Pulmonary,Alveolus, Pulmonary,Pulmonary Alveolus
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005260 Female Females
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
January 2009, Zhonghua yi xue za zhi,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
June 2002, The Israel Medical Association journal : IMAJ,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
December 2023, Chinese medical journal,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
November 2007, Clinical rheumatology,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
May 2023, Cureus,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
April 2023, Pediatric pulmonology,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
August 2011, Rheumatology international,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
December 2008, Journal of the National Medical Association,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
October 2020, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
L Kovács, and J Simon, and A Kovács, and A Pócsik, and I Boros, and B Iványi, and G Pokorny
October 2010, Lupus,
Copied contents to your clipboard!